Vaccine List

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.

FLUAD is a vaccine that helps protect against the flu. FLUAD is for people aged 65 years and older. Vaccination with FLUAD may not protect all people who receive the vaccine.

Flublok and Flublok Quadrivalent vaccines are given to people 18 years of age and older to help prevent influenza disease caused by influenza A virus subtypes and influenza type B virus contained in the vaccine. 

FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older.

FLUVIRIN® (Influenza Virus Vaccine) is an inactivated subunit influenza virus vaccine indicated for active immunization of persons aged 4 years and older against influenza disease caused by influenza virus subtypes A and B included in the vaccine.

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone High-Dose vaccine is given to people 65 years of age and older.

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Quadrivalent vaccine is given to people 6 months of age and older.

GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) helps protect girls and women ages 9 to 26 against cervical, vaginal, vulvar, and anal cancers and genital warts caused by 9 types of HPV. GARDASIL 9 helps protect boys and men ages 9 to 26 against anal cancer and genital warts caused by those same HPV types.
GARDASIL 9 may not fully protect everyone, nor will it protect against diseases caused by other HPV types or against diseases not caused by HPV.
GARDASIL 9 does not prevent all types of cervical cancer, so it’s important for women to continue routine cervical cancer screenings. GARDASIL 9 does not treat cancer or genital warts.
GARDASIL 9 is a shot that is usually given in the arm muscle. GARDASIL 9 may be given as 2 or 3 shots.

HAVRIX is a vaccine indicated for active immunization against disease
caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons
12 months of age and older. Primary immunization should be administered at
least 2 weeks prior to expected exposure to HAV.

Imovax Rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies.
Imovax Rabies vaccine is approved for use in all age groups.

MENHIBRIX is a vaccine indicated for active immunization to prevent
invasive disease caused by Neisseria meningitidis serogroups C and Y and
Haemophilus influenzae type b. MENHIBRIX is approved for use in children
6 weeks of age through 18 months of age.

M-M-R ® II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

PENNVAX®-GP is a developmental vaccine to prevent and treat HIV strains primarily present in Africa, Asia, Europe, and North America. It is intended to induce broad antibody and T-cell immune responses. This multi-subtype vaccine is based on optimized synthetic immunogens targeting two env antigens as well as gag and pol antigens—providing global coverage against HIV-1 subtypes. It is delivered using Inovio’s CELLECTRA® electroporation device. PENNVAX-GP is our lead preventive and therapeutic HIV DNA vaccine candidate. A phase I study is currently being conducted in collaboration with the HIV Vaccine Trials Network (HVTN).

Inovio’s PENNVAX-GP HIV vaccine is also being tested in combination with other novel DNA vaccine constructs encoding for new HIV envelope proteins in a five year preclinical program. Preclinical studies are being funded by the National Institute of Allergy and Infectious Diseases (NIAID).

Prevnar 13® is a vaccine indicated in children 6 weeks through 17 years (prior to the 18th birthday) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and for children 6 weeks through 5 years of age (prior to the 6th birthday) for the prevention of otitis media caused by 7 of the 13 serotypes in the vaccine
In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes in the vaccine
Prevnar 13® does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine

RABAVERT is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups.

ROTARIX is a vaccine indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series. ROTARIX is approved for use in infants 6 weeks to 24 weeks of age.

Sanofi Pasteur confirms that YF-VAX® (Yellow Fever Vaccine) is unavailable to order in the U.S. until mid-2018 as the company transitions production to a new state-of-the-art facility, which is expected to occur in 2018.

Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine available in the US through an Expanded Access Investigational New Drug Application (IND). Manufactured by Sanofi Pasteur in France, this vaccine, STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in over 70 countries. However, it is considered investigational in the US, as it is not a US-licensed product.

The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites. Working closely with the CDC, geographically distributed sites throughout the US were identified for inclusion in the program so patients can have continued access to yellow fever vaccine.

TRUVADA for PrEP (pre-exposure prophylaxis) is a prescription medicine that is used together with safer sex practices to help reduce the risk of getting HIV-1 through sex. This use is only for HIV-negative adults who are at high risk of getting HIV-1. To help determine your risk of getting HIV-1, talk openly with your healthcare provider about your sexual health.

TYPHIM Vi is a sterile solution, prepared from the purified polysaccharide capsule of
Salmonella typhi (Ty 2 strain). The purified polysaccharide capsule is diluted in
isotonic buffer solution which contains phenol as preservative. The vaccine is a clear,
colourless solution. Each single dose of 0.5 mL is formulated to contain 0.025
milligrams of purified capsular polysaccharide, preserved with phenol (less than 1.25
mg per dose). The isotonic buffer solution contains 4.15 mg of sodium chloride,
0.065 mg of sodium phosphate dibasic dihydrate and 0.023 mg of sodium phosphate
monobasic.

VARIVAX is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age or older.
Each dose is approximately 0.5 mL after reconstitution and is administered by subcutaneous injection.

Vaxchora is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.

YF-VAX is indicated for active immunization for the prevention of yellow fever in persons 9
months of age and older in the following categories: Persons Living in or Traveling to Endemic Areas,
Persons Travelling Internationally Through Countries with Yellow Fever, Laboratory Personnel